Physical Therapists in Tipp City, OH Accepting Medicare
8 Physical Therapists found. Showing 1 - 8
 Mrs. Jennifer Braun Ambos, PT Physical Therapist - Orthopedic Medicare: Not Enrolled in Medicare Practice Location: 25 S Tippecanoe Dr, Tipp City, OH 45371 Phone: 937-669-5757 |
Kaitlin Shoemaker Lunsford, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr Ste 120, Tipp City, OH 45371 Phone: 931-669-5757 |
 Aaron Cingle, PT, DPT Physical Therapist - Orthopedic Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr Ste 120, Tipp City, OH 45371 Phone: 937-669-5757 Fax: 937-669-1270 |
Heather Marie Rasper Tippie, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr, Tipp City, OH 45371 Phone: 937-669-5757 Fax: 937-669-1270 |
Dorothy Sue Snavley Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr, Tipp City, OH 45371 Phone: 937-669-5757 Fax: 937-669-1270 |
Mrs. Amy M Winner, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr Ste 120, Tipp City, OH 45371 Phone: 937-669-5757 |
Dr. Brian Edward Jans, PT Physical Therapist - Sports Medicare: Not Enrolled in Medicare Practice Location: 450 N Hyatt St, Suite 102, Tipp City, OH 45371 Phone: 937-440-7152 |
Bryan Ackerson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 70 Weller Dr, Tipp City, OH 45371 Phone: 937-669-5757 |
News Archive
Naurex reports positive results from GLYX-13 Phase IIa trial on depression
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.
Frequent, potentially avoidable readmissions are major driver of pediatric health care costs
Among a group of children's hospitals, nearly 20 percent of admissions and one-quarter of inpatient expenditures were accounted for by a small percentage of patients who have frequent recurrent admissions, according to a study in the February 16 issue of JAMA.
Biomet fourth quarter net sales increase 3% to $739.5 million
Biomet, Inc. announced today preliminary financial results for its fourth quarter and fiscal year ended May 31, 2012. The final results for the three and twelve months ended May 31, 2012 will be made available to the public with the filing of Biomet's Form 10-K for fiscal year 2012 and will include the finalization of a non-cash goodwill and intangible asset impairment charge as further described below and certain income tax accounts.
Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.
Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.
› Verified 4 days ago
Optometrists
Physical Therapists
Chiropractors
Speech-Language Pathologists
Podiatrists
Occupational Therapists